Skip to main content
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd — Investor Relations & Filings

Ticker · RGC ISIN · KYG7487R1002 US Manufacturing
Open in API
Filings indexed 80 across all filing types
Latest filing 2026-05-22 Capital/Financing Update
Country US United States of America
Listing US RGC

About Regencell Bioscience Holdings Ltd

https://www.regencellbioscience.com/

Regencell Bioscience Holdings Ltd. is an early-stage bioscience company that focuses on the research, development, and commercialization of proprietary Traditional Chinese Medicine (TCM) formulations. The company's primary therapeutic focus is on treating neurocognitive and neurodevelopmental disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). It aims to develop natural and effective treatments to improve the quality of life for patients and their families, with the goal of becoming a global market leader in this field.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Capital/Financing Update Classification · 75% confidence The document is a Form 6-K (a regulatory filing by a foreign private issuer) whose Exhibit 99.1 is a press release announcing the closing of a registered direct offering of ordinary shares. This is clearly an update on a fundraising/financing activity, matching the Capital/Financing Update category (CAP).
2026-05-22 English
PROSPECTUS SUPPLEMENT
Share Issue/Capital Change Classification · 80% confidence The document is a SEC prospectus supplement (Form 424B5) and base prospectus (Form F-3) describing a registered direct offering of 985,222 ordinary shares by Regencell Bioscience Holdings Limited. It provides detailed terms of the share issuance, offering price, placement agent fees, use of proceeds, risk factors, and legal matters—all hallmarks of a new share issue transaction. This is not a periodic financial report, earnings release, or audit report; it is a primary offering document announcing and detailing a new share issuance. Accordingly, it falls under Share Issue/Capital Change (SHA).
2026-05-19 English
REPORT OF FOREIGN PRIVATE ISSUER
Share Issue/Capital Change Classification · 85% confidence The document is a Form 6-K current report by a foreign private issuer announcing a registered direct offering of ordinary shares (new share issuance and fundraising). It is not a full financial report but a financing transaction announcement. This fits “Share Issue/Capital Change” (SHA).
2026-05-19 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 82% confidence The document is a Form 6-K “Report of Foreign Private Issuer” under the Securities Exchange Act, containing an exhibit index referencing a press release for a registered direct offering. It is a short regulatory submission (under 5,000 characters) that merely furnishes an external press release rather than providing substantive financial data or narrative. Under the classification rules, this is a general regulatory filing, not the actual financing document or annual/interim report, so it falls into the fallback category Regulatory Filings (RNS).
2026-05-19 English
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes exhibits such as a sales agreement, legal opinion, and consent, but does not contain financial statements or detailed financial analysis. The document is relatively short (2469 characters) and primarily serves as a regulatory filing to disclose material documents and legal opinions. It does not represent an annual report, earnings release, or other detailed financial report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2026-03-30 English
6-K - Regencell Bioscience Holdings Ltd (0001829667) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about an at-the-market offering of ordinary shares, indicating a financing activity. The document length is short (1710 characters) and it contains the actual press release as an exhibit, not just an announcement of a report. Form 6-K filings typically provide updates on material events between annual reports for foreign issuers. Given the content focuses on a capital raising activity, the most appropriate classification is Capital/Financing Update (CAP).
2026-03-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.